Previous close | 101.40 |
Open | 100.20 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 100.20 - 101.60 |
52-week range | 100.20 - 108.00 |
Volume | |
Avg. volume | 0 |
Market cap | 260.608B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 21.04 |
EPS (TTM) | N/A |
Earnings date | 30 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial